Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 445 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Unfractionated Heparin Clear all
Completed Phase 2 Interventional

Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis

NCT00395772
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Xarelto (Rivaroxaban, BAY59-7939), (LMW) Heparin + Vitamin K Antagonist
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
5
States / cities
Albuquerque, New Mexico • Chapel Hill, North Carolina • Fredericksburg, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Oct 17, 2026, 9:29 AM EDT
Completed Phase 2Phase 3 Interventional

BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery

NCT00097357
View directory record Official record
Conditions
Venous Thrombosis, Pulmonary Embolism
Interventions
Apixaban, Enoxaparin, Warfarin, Enoxaparin Placebo, Apixaban Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 17, 2026, 9:29 AM EDT
Not listed Phase 4 Interventional

Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation

NCT03965208
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation Complication, Anticoagulants
Interventions
Bivalirudin, Unfractionated heparin
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 17, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

NCT03891524
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee
Interventions
JNJ-70033093 25 mg, JNJ-70033093 50 mg, JNJ-70033093 100 mg, JNJ-70033093 200 mg, Placebo, Enoxaparin 40 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
50 Years and older
Enrollment
1,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 17, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Results available

Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement

NCT00152971
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee, Thromboembolism
Interventions
Dabigatran Dose 1 - day 2 to completion, Dabigatran Dose 1 - day 1, Dabigatran Dose 2 - day 2 to completion, Dabigatran Dose 2 - day 1, Enoxaparin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
59
States / cities
Birmingham, Alabama • Northport, Alabama • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 17, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Results available

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

NCT04401293
View directory record Official record
Conditions
Sars-CoV2, COVID
Interventions
Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 17, 2026, 9:29 AM EDT
Completed Not applicable Interventional

Inpatient Monitoring of Unfractionated Heparin

NCT06329921
View directory record Official record
Conditions
Blood Clot, Thrombosis
Interventions
PTT protocol, anti-Xa protocol
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 9:29 AM EDT
Completed Phase 4 Interventional

FREEDOM COVID-19 Anticoagulation Strategy

NCT04512079
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Enoxaparin, Apixaban
Drug
Lead sponsor
Valentin Fuster
Other
Eligibility
18 Years and older
Enrollment
3,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 17, 2026, 9:29 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

NCT00876915
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism
Interventions
dalteparin injection
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Sacramento, California • Buffalo, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Oct 17, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Results available

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

NCT00657150
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Enoxaparin, Dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,055 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Englewood, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 17, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Results available

The Randomized OPTIMAL-ACT Trial

NCT03772613
View directory record Official record
Conditions
Coronary Artery Disease, Ischemic Heart Disease, Anticoagulant-induced Bleeding, Coronary Syndrome
Interventions
Unfractionated heparin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 17, 2026, 9:29 AM EDT
Recruiting Phase 2 Interventional

Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

NCT06394830
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
VNX001
Drug
Lead sponsor
Vaneltix Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Tucson, Arizona • Fresno, California • Tustin, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 17, 2026, 9:29 AM EDT
Withdrawn Not applicable Interventional

Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic Reactions in an Emergency Department

NCT00657228
View directory record Official record
Conditions
Anaphylaxis
Interventions
Intravenous heparin, Saline
Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 17, 2026, 9:29 AM EDT
Completed Phase 4 Interventional Results available

Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)

NCT00790907
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
3,235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Ocala, Florida • Albuquerque, New Mexico • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 17, 2026, 9:29 AM EDT
Completed Phase 3 Interventional

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

NCT01076764
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Otamixaban, Placebo (for Otamixaban), UFH, Placebo (for UFH), Eptifibatide, Placebo (for Eptifibatide)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
13,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
107
States / cities
Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 82 more
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 17, 2026, 9:29 AM EDT
Completed No phase listed Observational

Emulation of the RECORD3 Trial Using Healthcare Claims Data

NCT07599384
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolus
Interventions
Rivaroxaban, Enoxaparin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
149,248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 17, 2026, 9:29 AM EDT
Not listed No phase listed Observational

Assessment of Clinical Onset of IV Heparin in Interventional Cardiology and Cardiac Surgery

NCT04785885
View directory record Official record
Conditions
Transcatheter Aortic Valve Replacement, Cardiac Valve Annuloplasty
Interventions
iStat Handheld Blood Analyzer, Hemochron
Diagnostic Test
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 17, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Results available

PREVENTion of Clot in Orthopaedic Trauma

NCT02984384
View directory record Official record
Conditions
Blood Clot, Trauma
Interventions
Acetylsalicylic acid, Low Molecular Weight Heparin (LMWH)
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years and older
Enrollment
12,424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Tucson, Arizona • Miami, Florida • Indianapolis, Indiana + 16 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 17, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Results available

Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

NCT02873338
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Dociparstat sodium, Idarubicin, Cytarabine
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
23
States / cities
La Jolla, California • Denver, Colorado • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 17, 2026, 9:29 AM EDT
Terminated Not applicable Interventional Results available

Enoxaparin and/or Minocycline in Acute Stroke

NCT00836355
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Enoxaparin, Minocycline
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 95 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2016 · Synced Oct 17, 2026, 9:29 AM EDT
Recruiting Not applicable Interventional

KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure

NCT05879835
View directory record Official record
Conditions
Pediatric Intestinal Failure
Interventions
KiteLock 4% Sterile Catheter Lock Solution, Heparin Lock Solution
Device
Lead sponsor
SterileCare Inc.
Industry
Eligibility
4 Weeks to 18 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Boston, Massachusetts • Omaha, Nebraska • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 17, 2026, 9:29 AM EDT
Withdrawn Not applicable Interventional

Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients

NCT02707263
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
intravenous continuous infusion of heparin (IV UFH), Subcutaneous Heparin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 17, 2026, 9:29 AM EDT
Completed Phase 2 Interventional

Heparin Versus Lepirudin Flushes in Preventing Blockage of Venous Access Devices

NCT00039767
View directory record Official record
Conditions
Thrombosis
Interventions
Lepirudin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 9:29 AM EDT
Terminated Phase 2 Interventional

Paclitaxel for the Treatment of Upper-Extremity Arteriovenous Access Fistula Stenosis

NCT01868984
View directory record Official record
Conditions
Fistula Stenosis
Interventions
Paclitaxel, Standard Therapy
Drug · Procedure
Lead sponsor
Englewood Hospital and Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 17, 2026, 9:29 AM EDT